Ophthalmic Trials Australia | Teneriffe, Australia

Research site

Location

2/53 Commercial Rd, Teneriffe, Queensland, Australia

Site insights

Top conditions

Top treatments

AZR-MD-001

RHPRG4

TN-001

KIO-101

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Mark Hinds

Verified by this site

Active trials

3 of 9 total trials

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

rhPRG4-Sjögren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in su...

Enrolling

Sjögren's Syndrome

Drug: Vehicle Control

Drug: Recombinant Human Proteoglycan 4

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD relate...

Enrolling

Ocular Graft Versus Host Disease

Drug: rhPRG4 450ug/ml

Drug: Vehicle Control

Study of TN-001 Topical Eyedrops for Keratoconus

The goal of this clinical trial is to learn if TN-001, a new eye-drop therapy, is safe and well-tolerated in adult patients with progressive keratoco...

Invitation-only

Keratoconus

Drug: High-dose TGF-B3 and Dexamethasone Sodium Phosphate

Drug: Low-dose TGF-B3 and Dexamethasone Sodium Phosphate